Prostate Cancer Clinical Trial

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Summary

Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or Stage IV Prostate Cancer.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or Stage IV Prostate Cancer.

View Full Description

Full Description

Stage III or Stage IV Prostate Cancers receive Antineoplaston A10 and AS2-1 capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

To determine the efficacy of Antineoplaston therapy in patients with Stage III or Stage IV Prostate Cancer, as measured by an objective response to therapy (complete response, partial response or stable disease).
To determine the safety and tolerance of Antineoplaston therapy in patients with Stage III or Stage IV Prostate Cancer.
To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 4 months for 2 years, every 6 months for 2 years, and then annually for 2 years thereafter.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically proven stage III or IV adenocarcinoma of the prostate not potentially curable by surgery or radiotherapy
Measurable tumors or tumor markers
No response to antiandrogen withdrawal

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Karnofsky 60-100%

Life expectancy:

At least 3 months

Hematopoietic:

WBC at least 3000/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Bilirubin no greater than 2.5 mg/dL
SGOT no greater than 2 times normal
No hepatic failure

Renal:

BUN less than 60 mg/dL
Creatinine no greater than 2.5 mg/dL OR
Creatinine clearance greater than 60 mL/min
Blood ammonia normal
No chronic renal failure

Cardiovascular:

No severe heart disease

Pulmonary:

No severe lung disease

Other:

Fertile patients must use effective contraception during and for 4 weeks after study participation
No serious active infection or fever
No other concurrent serious disease
No other prior or concurrent malignancy within the past 2 years

PRIOR CONCURRENT THERAPY:

Biologic therapy:

At least 4 weeks since prior immunotherapy and recovered

Chemotherapy:

At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

At least 4 weeks since prior hormonal therapy and recovered
Prior corticosteroids for at least 2 months allowed, but must be on stable or decreasing dose during study participation

Radiotherapy:

See Disease Characteristics
At least 4 weeks since prior radiotherapy and recovered

Surgery:

See Disease Characteristics
At least 4 weeks since prior surgery and recovered

Other:

At least 4 weeks since prior experimental clinical trial
No other concurrent therapy for metastatic disease

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

16

Study ID:

NCT00003516

Recruitment Status:

Terminated

Sponsor:

Burzynski Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Burzynski Clinic
Houston Texas, 77055, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

16

Study ID:

NCT00003516

Recruitment Status:

Terminated

Sponsor:


Burzynski Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider